ArticleInternational journal of clinical and experimental pathology2015
TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- Probiotics ameliorate H. pylori-associated gastric β-catenin and COX-2 carcinogenesis signaling by regulating miR-185.Journal of biomedical science · 2025Trial
- Mechanisms and functions of the TRIM protein family in digestive system cancers.Journal of translational medicine · 2026Review
- TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-β-catenin axis.Cell communication and signaling : CCS · 2025Article
- Exploring the pathogenesis of MAFLD from an immunological perspective: from the perspective of the cGAS/STING/NF-κB signaling pathway.Frontiers in immunology · 2025Review
- Therapeutic potential of TRIM family proteins in gastric cancer: from signaling pathway regulation to precision targeting strategies.Frontiers in oncology · 2025Review
- Review
- TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond.Cancer metastasis reviews · 2024Review
- Trim13-induced ubiquitination of RPS27A inhibits the progression of lung cancer by depending on the inactivation of NF-κB signaling pathway.Physiological reports · 2024Article
- TRIM25, TRIM28 and TRIM59 and Their Protein Partners in Cancer Signaling Crosstalk: Potential Novel Therapeutic Targets for Cancer.Current issues in molecular biology · 2024Review
- Mesenchymal Stem Cells Accelerate Recovery of Acetic Acid-Induced Chronic Gastric Ulcer by Regulating Ekt/Akt/TRIM29 Axis.Stem cells international · 2024Article
- Exploring the Mechanisms, Biomarkers, and Therapeutic Targets of TRIM Family in Gastrointestinal Cancer.Drug design, development and therapy · 2024Review
- Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape.Journal of advanced research · 2023Review
- TRIM14 Overexpression Induces Chemoresistance and Malignant Behaviors of Hepatocellular Carcinoma Cells by Activating the STAT3/HIF-1α Pathway.International journal of molecular sciences · 2023Article
- lncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression.Acta biochimica et biophysica Sinica · 2023Article
- UPS: Opportunities and challenges for gastric cancer treatment.Frontiers in oncology · 2023Review
- The Roles of microRNA miR-185 in Digestive Tract Cancers.Non-coding RNA · 2022Review
- Clinical significance of TRIM29 expression in patients with gastric cancer.Gastroenterology and hepatology from bed to bench · 2022Article
- Identification of Signature Genes in the PD-1 Relative Gastric Cancer Using a Combined Analysis of Gene Expression and Methylation Data.Journal of oncology · 2022Article
- E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.Journal of translational medicine · 2021Article
- Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.Journal of molecular medicine (Berlin, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tripartite motif-containing 29 (TRIM29) belongs to TRIM family of transcription factors and may function as an oncogene or a tumor suppressor depending on the tumor types. Overexpression of TRIM29 is frequently observed in gastric cancer but the underlying mechanisms remain largely unknown. In the present study, we investigated the function of TRIM29 in gastric cancer-derived cell line MGC803. RNAi-mediated silencing of TRIM29 resulted in significantly reduced cell proliferation and colony formation, as well as G1-S cell cycle arrest and apoptosis. Interestingly, expression levels of β-catenin, cyclin D1 and c-Myc were all downregulated in TRIM29 knockdown cells, indicating that TRIM29 is involved in regulating the activity of Wnt/β-catenin signaling pathway. Furthermore, based on target prediction and luciferase assay, we identified TRIM29 as a potential target of miR-185, which is frequently downregulated in gastric cancer. Over-expression of miR-185 in MGC803 cells inhibited TRIM29 expression and activity of Wnt/β-catenin signaling. Taken together, our results suggest that TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
Indexed as
Identifiers
26191199PMC4503071W2409850560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.